Article Text

Download PDFPDF
Elevated levels of anti-carbamylated protein antibody in patients with rheumatoid arthritis: association with disease activity and bone destruction
  1. Bei Zhang1,
  2. Yimeng Lei1,
  3. Xin Li2,
  4. Ziyu Gao3,
  5. Liping Xia1,
  6. Jing Lu1,
  7. Hui Shen1
  1. 1 Department of Rheumatology, China Medical University First Hospital, Shenyang, Liaoning, China
  2. 2 Department of Rheumatology, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
  3. 3 China Medical University First Hospital, Shenyang, Liaoning, China
  1. Correspondence to Dr Hui Shen, Department of Rheumatology, China Medical University First Hospital, Shenyang 110001, Liaoning, China; shenhuicam{at}sohu.com

Abstract

To measure the serum levels of anticarbamylated protein (CarP) antibodies in patients with rheumatoid arthritis (RA) in China and to evaluate the association of anti-CarP antibodies with clinical parameters and disease activity. 260 Chinese patients with RA, 40 patients with osteoarthritis (OA), 88 patients with spondyloarthritis (SpA) and 77 healthy controls were included. The serum levels of anti-CarP antibodies were detected by ELISA. Blood tests to detect the anticyclic citrullinated peptide (CCP) antibody level, rheumatoid factor (RF) level, erythrocyte sedimentation rate, C reactive protein level and Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR) were performed by standard methods. Bone erosion was assessed by colour Doppler ultrasonography. A total of 18.8% of patients with RA and 9.4% of anti-CCP antibody and RF-double-negative patients were positive for anti-CarP antibody. The anti-CarP antibody level was significantly higher in patients with RA than in patients with OA or SpA and in healthy controls. Univariate and multivariate analyses showed that the level of anti-CarP antibody was positively correlated with DAS28-ESR; the higher a level of serum anti-CarP antibody, the higher the DAS28-ESR score. Anti-CarP-positive patients had higher disease activity scores than anti-CarP-negative patients. Moreover, anti-CarP-positive patients had a higher risk of developing bone erosion. The anti-CarP antibody was found to play an important role in the diagnosis of RA, especially in anti-CCP antibody and RF-double-negative patients. The anti-CarP antibody is a potential marker of disease activity and bone erosion in RA.

  • anticarbamylated protein antibody
  • rheumatoid arthritis
  • disease activity
  • bone destruction
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors HS, LX and JL designed the study and revised the manuscript. BZ and YL performed the experiments. BZ drafted the manuscript. BZ, XL and ZG analyzed the data.

  • Funding This study was supported by grants from the National Natural Science Foundation of China (number 81373219) and the Liaoning Education Department (number JC2019009).

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval This study was approved by the ethics committee of the First Affiliated Hospital of China Medical University (2019-125-2) and complies with the Declaration of Helsinki. Written informed consent was given by all patients.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Data availability statement Data are available upon reasonable request. no additional data.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.